Berlin - Delayed Quote EUR

Annovis Bio Inc (07X.BE)

2.5250

+0.0800

+(3.27%)

As of 2:05:08 PM GMT+1. Market Open.

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference. Presentation details Date: February 11, 2025Time: 12:40 – 1:10 p.m. E

GlobeNewswire 6 days ago

ANVS
Annovis begins treatment of subjects in Alzheimer’s trial

The treatment in the placebo-controlled, double-blind trial is said to span 18 months.

Clinical Trials Arena 6 days ago

ANVS
Annovis Bio announces first patients entered Phase 3 study of buntanetap

Annovis Bio (ANVS) announced that the first two patients have been entered into the Phase 3 study evaluating buntanetap in early AD. “The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward market approval and addressing the unmet medical need of millions of patients. Our previous trials have delivered compelling results, and we have meticulously designed a comprehensive protocol to evaluate both the symptomatic and potential disease-modifying effe

TipRanks 7 days ago

ANVS
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. "The launch of our highly anticipated AD study is a significant milestone in adv

GlobeNewswire 8 days ago

ANVS
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering

GlobeNewswire 8 days ago

ANVS
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per s

GlobeNewswire 10 days ago

ANVS
Annovis Bio, Inc. Announces Proposed Public Offering

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it intends to offer to sell common stock and warrants in an underwritten public offering. All of the common stock and warrants are to be sold by the Company. ThinkEquity is acting as sol

GlobeNewswire 12 days ago

ANVS
Annovis Bio granted U.S. patent covering buntanetap

Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based on buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes, which can be applicable to such conditions as stroke, ischemia, traumatic brain injury, micro infarcts, and other forms of acute injuries. The patent has already been granted in the EU, Japan, and worldwide. With th

TipRanks 29 days ago

ANVS
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based on buntanetap’s ability to reduce neu

GlobeNewswire 30 days ago

ANVS
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA granted clearance for Annovis to proceed with

GlobeNewswire last month

ANVS
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace

LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio’s (NYSE: ANVS) recent feature on Today’s Marketplace (TMP) as part of its commitment to amplifying industry leaders’ voices through targeted distribution channels. The full interview can be viewed at https://ibn.fm/m7gvX. This TMP episode highlights an exclusive interview w

GlobeNewswire 2 months ago

ANVS
Annovis to Host Year-End Investor Webcast on December 11, 2024

MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST. Webcast Details: Date: December 11, 2024Time: 4:30 PM ESTRegistration Link: Register Here Dr. Maria Maccecchini, Founder, President, and CEO of Annovis, will lead the webcast, providing a comprehensive update on the

GlobeNewswire 2 months ago

ANVS
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that its President and CEO, Maria Maccecchini, Ph.D., has been invited to speak at the National Institute on Aging (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational

GlobeNewswire 3 months ago

ANVS
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "The third quarter was marked by important milestones outlining the next steps for buntanetap," said Maria

GlobeNewswire 3 months ago

ANVS
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 3 months ago

ANVS
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct,

GlobeNewswire 3 months ago

ANVS
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. T

GlobeNewswire 3 months ago

ANVS
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The event will be held from October 29 to November 1, 2024, in Madrid, Spain. Dr.

GlobeNewswire 3 months ago

ANVS
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug

The market sees hope to Annovis to become profitable

GuruFocus.com 3 months ago

ANVS
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs

MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivota

GlobeNewswire 3 months ago

ANVS

Performance Overview

Return	07X.BE	S&P 500
YTD	-50.30%	+2.90%
1-Year	-73.42%	+22.18%
3-Year	-80.27%	+36.96%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Annovis Bio Inc (07X.BE)

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Annovis begins treatment of subjects in Alzheimer’s trial

Annovis Bio announces first patients entered Phase 3 study of buntanetap

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Annovis Bio, Inc. Announces Proposed Public Offering

Annovis Bio granted U.S. patent covering buntanetap

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace

Annovis to Host Year-End Investor Webcast on December 11, 2024

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs

Performance Overview